A STUDY TO EVALUATE THE EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR AND RENAL OUTCOMES OF PATIENTS WITH TYPE 2 DIABETES MELLITUS AT A TERTIARY CARE HOSPITAL IN TELANGANA

K. VASANTHA KUMARI; MEHER KOUNEN FATIMA; FARHEEN SULTANA; CHAKRADHAR T.; MOHD MOOSA QUADRI

doi:10.22159/ijpps.2025v17i3.53190

Authors

K. VASANTHA KUMARI Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India
MEHER KOUNEN FATIMA Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India
FARHEEN SULTANA Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India https://orcid.org/0009-0004-6818-0893
CHAKRADHAR T. Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India https://orcid.org/0009-0000-7208-001X
MOHD MOOSA QUADRI Department of Pharmacology, Osmania Medical College, Koti, Hyderabad, India https://orcid.org/0009-0006-3974-1780

DOI:

https://doi.org/10.22159/ijpps.2025v17i3.53190

Keywords:

Type 2 diabetes mellitus, Metformin, Empagliflozin, Cardiovascular outcomes, Renal outcomes

Abstract

Objective: The objective of this study is to evaluate the effects of Empagliflozin on cardiovascular and renal outcomes in Type 2 Diabetes Mellites (T2DM) patients, particularly focusing on improvements in glycemic control, weight, blood pressure, and renal function after 6 mo of treatment.

Methods: A cross-sectional observational study was conducted at Osmania Medical College and Hospitals, Hyderabad, over six months, involving 120 patients with T2DM. The patients were randomly divided into two groups. Group 1 patients received standard Oral Hypoglycemic Agents (OHAs) such as Metformin. Group 2 patients received the same OHAs along with Empagliflozin 10 mg. Baseline and post-treatment data for key parameters such as blood glucose levels, blood pressure, Body Mass Index (BMI), and renal function markers (e. g., serum creatinine) were collected. The t-test was used for statistical analysis to compare pre-and post-treatment values.

Results: After six months of treatment, the following significant improvements were observed in the group receiving Empagliflozin: Diastolic blood pressure: A significant reduction of 7 mmHg (p = 0.00066), BMI: A reduction of 1.6 units (p = 0.0107), Key glycemic parameters showed significant improvements: Fasting Blood Sugar (FBS): p = 0.000212, Random Blood Sugar (RBS): p<0.00001, HbA1c levels: p = 0.000147. These results indicate that Empagliflozin significantly improved glycemic control, blood pressure, and weight, which are all key factors contributing to improved cardiovascular and renal health in T2DM patients.

Conclusion: The addition of Empagliflozin to standard T2DM treatment resulted in significant improvements in glycemic control, body weight, and blood pressure, particularly diastolic blood pressure, over the 6-month study period. These changes are likely to contribute to improved cardiovascular and renal outcomes in patients with T2DM. Thus, Empagliflozin offers a valuable therapeutic option for enhancing overall disease management in T2DM patients with complications.

Downloads

Download data is not yet available.

References

World Health Organization. The top 10 causes of death. Available from: http://www.who.int/en/news-room/fact-sheets/detail/the-top-10-causes-of-death. [Last accessed on 02 Feb 2025].

Pradeepa R, Mohan V. Epidemiology of type 2 diabetes in India. Indian J Ophthalmol. 2021;69(11):2932-8. doi: 10.4103/ijo.IJO_1627_21, PMID 34708726.

Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, Joshi S, Bajaj S, Jabbar PK, Das HK, Kumar A, ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023 Jul;11(7):474-89.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M. Management of hyperglycemia in type 2 diabetes 2015: a patient-centered approach: update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetes Care. 2015;38(1):140-9. doi: 10.2337/dc14-2441, PMID 25538310.

Ramanathan B, Duraisamy R, Venkatramanasami BT, Abbas MK, Balamurugan A. Association of glycaemic status and outcomes in diabetic foot problems: a retrospective evidence from South India. J Basic Clin Physiol Pharmacol. 2021;33(2):155-62. doi: 10.1515/jbcpp-2020-0198, PMID 33618439.

Ismail L, Materwala H, Al Kaabi J. Association of risk factors with type 2 diabetes: a systematic review. Comput Struct Biotechnol J. 2021 Mar 10;19:1759-85. doi: 10.1016/j.csbj.2021.03.003, PMID 33897980.

Bhatti JS, Sehrawat A, Mishra J, Sidhu IS, Navik U, Khullar N. Oxidative stress in the pathophysiology of type 2 diabetes and related complications: current therapeutics strategies and future perspectives. Free Radic Biol Med. 2022 May 1;184:114-34. doi: 10.1016/j.freeradbiomed.2022.03.019, PMID 35398495.

Batista TM, Haider N, Kahn CR. Defining the underlying defect in insulin action in type 2 diabetes. Diabetologia. 2021;64(5):994-1006. doi: 10.1007/s00125-021-05415-5, PMID 33730188.

Lunati ME, Cimino V, Gandolfi A, Trevisan M, Montefusco L, Pastore I. SGLT2-inhibitors are effective and safe in the elderly: the sold study. Pharmacol Res. 2022 Sep;183:106396. doi: 10.1016/j.phrs.2022.106396, PMID 35970329.

Triplitt CL, Reasner CA, Isley WL. Diabetes mellitus. In: Di Piro JT, Talbert RL, Yee GC, editors. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York: McGraw-Hill; 2008. p. 1205-41.

Frampton JE. Empagliflozin: a review in type 2 diabetes. Drugs. 2018 Jul;78(10):1037-48. doi: 10.1007/s40265-018-0937-z, PMID 29946963.

Paczkowska A, Hoffmann K, Michalak M, Bryl W, Kopciuch D, Zaprutko T. A comparison between the therapeutic effect of metformin alone versus combination therapy with insulin in uncontrolled non-adherence patients with type 2 diabetes: six months follow up. Diabetes Metab Syndr Obes. 2021 Jul 14;14:3243-52. doi: 10.2147/DMSO.S317659, PMID 34285531.

Anker SD, Usman MS, Butler J. SGLT2 inhibitors: from antihyperglycemic agents to all around heart failure therapy. Circulation. 2022 Jul 26;146(4):299-302. doi: 10.1161/circulationaha.122.060348, PMID 35877834.

Ndefo UA, Anidiobi NO, Basheer E, Eaton AT. Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type 2 diabetes. PT. 2015 Jun;40(6):364-8, PMID 26045645.

Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I. Empagliflozin treatment effects across categories of baseline HbA1c body weight and blood pressure as an add on to metformin in patients with type 2 diabetes. Diabetes Obes Metab. 2021 Feb;23(2):425-33. doi: 10.1111/dom.14234, PMID 33084149.

Vallon V, Verma S. Effects of SGLT2 inhibitors on kidney and cardiovascular function. Annu Rev Physiol. 2021 Feb 10;83:503-28. doi: 10.1146/annurev-physiol-031620-095920, PMID 33197224.

Min SH, Yoon JH, Hahn S, Cho YM. Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis. Diabetes Metab Res Rev. 2017;33(1):e2818. doi: 10.1002/dmrr.2818, PMID 27155214.

Chacko J, Dhandapani S, Jahagiridhar V, Swaminathan K. The effects of empagliflozin on cardiometabolic risk factors in patients with type 2 diabetes: a short-term observational study. Indian J Pharmacol. 2021 May-Jun;53(3):229-33. doi: 10.4103/ijp.IJP_669_18, PMID 34169909.

Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;8(4):262-75.e9. doi: 10.1016/j.jash.2014.01.007, PMID 24602971.

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S. Empagliflozin cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720, PMID 26378978.

Takata T, Isomoto H. Pleiotropic effects of sodium-glucose cotransporter 2 inhibitors: renoprotective mechanisms beyond glycemic control. Int J Mol Sci. 2021 Apr 22;22(9):4374. doi: 10.3390/ijms22094374, PMID 33922132.